Election aftermath: what now for life sciences?
Following the unprecedented 2016 U.S. Presidential election, we discuss the implications of potential policies of the new government administration on the life sciences industry.
Taking a risk-based approach to EU MDR compliance
The European Parliament has published its EU Medical Device Regulation, setting the stage for sweeping changes across the medical device value chain.
Galvanizing innovation in medtech – and biopharma
How Galvani Bioelectronics, a joint venture of GlaxoSmithKline and Verily, could catalyze future innovations in both medtech and biopharma.
New normal: US$200b+ M&A as big pharma leads way
Life sciences M&A tops US$200b again. 90% of the acquisitions are US-based while big pharma steps up with over 50% of the announced M&A value.
Investing in precision medicine diagnostics
Over the decade, there has been robust growth in precision therapeutics as biopharmas seek to develop medicines to be targeted for specific patient populations.
Driving value and cost savings in Asia-Pacific
Whether renewing contracts or negotiating new ones, pharmaceutical companies should always set clear goals and commit to making investments to achieve long-term benefits.
Building connected health services
As demographic, digital and financial forces transform how health care is delivered, it’s not first-in-class medicine or technology that determines value -- it’s data.
Pulse of the industry 2016
Despite a buoyant M&A market and solid performance in venture capital raised, financial metrics show the global medtech industry continues to struggle to grow.
The rise of unbranded generics
With cost containment a key priority for governments and payers, Asian markets will likely prioritize initiatives that shift drug use from branded to unbranded generics.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:

Biotechnology
More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.
But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.
We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.
We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.
So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.
Take a closer look:
Pharmaceutical
Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.
We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.
Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.
Take a closer look:
Medical technology
Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.
Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.
Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.
From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.
Take a closer look: